A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, and immunogenicity of ABP 980 and pertuzumab combined in a single infusion in healthy subjects
Main Authors: | V. Hanes, V. Chow, T. Stewart, A. Puri |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-04-01
|
Series: | Breast |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977621001697 |
Similar Items
-
P815: PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY OF ABP 959 AND ECULIZUMAB REFERENCE PRODUCT: UNBOUND ECULIZUMAB AND CH50 FROM THE RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE STUDY IN HEALTHY VOLUNTEERS
by: V. Hanes, et al.
Published: (2022-06-01) -
Pertuzumab-mediated Cardiotoxicity: A Single Center Study.
by: Özgür Özyilkan, et al.
Published: (2023-06-01) -
Lavender aromatherapy on anxiety and depression in patients with Acute Coronary Syndrome: a single-blind randomized clinical trial
by: Nategh Mohammad, et al.
Published: (2022-08-01) -
ABP la evaluación del aprendizaje basado en problemas - ABP ABP-experimentación y validación.
by: Ofelia Villegas Muñoz
Published: (2004-02-01) -
a0(980)–f0(980) mixing in χc1 decay
by: Bayar M, et al.
Published: (2019-01-01)